全文获取类型
收费全文 | 6916篇 |
免费 | 358篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 44篇 |
儿科学 | 178篇 |
妇产科学 | 53篇 |
基础医学 | 946篇 |
口腔科学 | 224篇 |
临床医学 | 386篇 |
内科学 | 1454篇 |
皮肤病学 | 127篇 |
神经病学 | 857篇 |
特种医学 | 316篇 |
外科学 | 1381篇 |
综合类 | 27篇 |
预防医学 | 219篇 |
眼科学 | 91篇 |
药学 | 391篇 |
中国医学 | 15篇 |
肿瘤学 | 610篇 |
出版年
2023年 | 69篇 |
2022年 | 35篇 |
2021年 | 171篇 |
2020年 | 106篇 |
2019年 | 166篇 |
2018年 | 177篇 |
2017年 | 139篇 |
2016年 | 146篇 |
2015年 | 200篇 |
2014年 | 236篇 |
2013年 | 243篇 |
2012年 | 356篇 |
2011年 | 371篇 |
2010年 | 228篇 |
2009年 | 177篇 |
2008年 | 296篇 |
2007年 | 321篇 |
2006年 | 308篇 |
2005年 | 286篇 |
2004年 | 319篇 |
2003年 | 289篇 |
2002年 | 294篇 |
2001年 | 230篇 |
2000年 | 231篇 |
1999年 | 194篇 |
1998年 | 86篇 |
1997年 | 60篇 |
1996年 | 74篇 |
1995年 | 59篇 |
1994年 | 58篇 |
1993年 | 36篇 |
1992年 | 145篇 |
1991年 | 118篇 |
1990年 | 124篇 |
1989年 | 115篇 |
1988年 | 92篇 |
1987年 | 76篇 |
1986年 | 67篇 |
1985年 | 75篇 |
1984年 | 54篇 |
1983年 | 52篇 |
1982年 | 24篇 |
1979年 | 49篇 |
1977年 | 33篇 |
1974年 | 40篇 |
1973年 | 32篇 |
1972年 | 24篇 |
1971年 | 24篇 |
1968年 | 24篇 |
1967年 | 23篇 |
排序方式: 共有7319条查询结果,搜索用时 15 毫秒
1.
Tomoyasu Tachibana Shin Kariya Yoji Wani Yasutoshi Komatsubara Yuto Naoi Kazunori Kuroda Soichiro Fushimi Machiko Hotta Katsuya Haruna Tami Nagatani Takuma Makino Yuko Kataoka Kazunori Nishizaki 《Auris, nasus, larynx》2021,48(1):154-160
ObjectivesSialolipoma has been classified as a benign soft tissue lesion in the 2017 World Health Organization classification of head and neck tumors. To our knowledge, only one case of laryngeal sialolipoma has been reported in the English literature. We conducted a retrospective study to identify clinical characteristics of supraglottic sialolipoma-like lesion and differentiate it from other supraglottic subepithelial masses.MethodsMedical records of 16 patients with supraglottic subepithelial benign mass lesions who underwent histological evaluation between 2003 and 2019 were retrospectively analyzed. Sialolipoma-like lesion was defined as a local finding of a well-circumscribed gross mass with pathological presence of salivary gland-like parenchymal lobules with evenly interspersed adipose tissue.ResultsEight patients showed histological positivity for sialolipoma-like lesion, 3 for amyloidosis, 2 for hemangioma, and 1 each for cyst, lymphoid hyperplasia, and chondrometaplasia. Sialolipoma-like lesion tended to be predominant among men; those affected had a mean age of 52.8 (range, 39–74) years. By contrast, among patients with amyloidosis, the ratio of men to women was 1:2 (100% vs. 33%; p = 0.055). Fiberscopic examination of all patients with sialolipoma-like lesions identified well-circumscribed, yellowish masses, closely resembling local amyloidosis findings. Sialolipoma-like lesion was associated with a significantly higher body-mass index (BMI; 27.4 ± 2.8 kg/m2) than amyloidosis (21.6 ± 1.4 kg/m2; p = 0.014). The transoral approach was used for lesion resection in all patients with sialolipoma-like lesion. No patient experienced postoperative recurrence.ConclusionLaryngeal sialolipoma-like lesion might be more prevalent than was previously reported, and histological examination is important to differentiate it from amyloidosis. Supraglottic sialolipoma-like lesion must be differentially diagnosed in patients with high BMI presenting with well-circumscribed, yellowish supraglottic masses. 相似文献
2.
3.
Katsuki Masahito Fujimura Miki Tashiro Ryosuke Tomata Yasutake Nishizawa Taketo Tominaga Teiji 《Neurosurgical review》2021,44(4):2191-2200
Neurosurgical Review - Superficial temporal artery (STA)–middle cerebral artery (MCA) anastomosis is a standard treatment for adult moyamoya disease (MMD) patients. Cerebral hyperperfusion... 相似文献
4.
5.
Shigeru YAMAGUCHI Hiroaki MOTEGI Yukitomo ISHI Michinari OKAMOTO Ryosuke SAWAYA Hiroyuki KOBAYASHI Shunsuke TERASAKA Kiyohiro HOUKIN 《Neurologia medico-chirurgica》2021,61(4):245
Bevacizumab (BEV) is a key anti-angiogenic agent used in the treatment for recurrent glioblastoma multiforme (GBM). The aim of this study was to investigate whether cytoreductive surgery prior to treatment with BEV contributes to prolongation of survival for patients with recurrent GBM. We retrospectively analyzed the treatment outcomes of 124 patients with recurrent GBM who were initially treated with the Stupp protocol between 2006 and 2019. Given that BEV has only been available in Japan since 2013, we grouped the patients into two groups according to the time of first recurrence: the pre-BEV group (N = 51) included patients who had recurrence before BEV approval, and the BEV group (N = 73) included patients with recurrence after BEV approval. The overall survival after first recurrence (OS-R) was analyzed according to the treatment strategy. Among 124 patients, 27 patients (19.4%) received cytoreductive surgery. There were nine cases in the pre-BEV group and 18 cases in the BEV group. Although the mean extent of resection for both groups was almost equal, OS-R was significantly different. The median OS-R was 8.1 m in the pre-BEV group and 16.3 m in the BEV group (P = 0.007). Multivariate analysis revealed that the unavailability of BEV postoperatively (P = 0.03) and decreasing performance status by surgery (P = 0.01) were significant poor prognostic factors for survival after surgery. With the advent of BEV, cytoreductive surgery might provide superior survival benefit at the time of GBM recurrence, especially in cases where surgery can be performed without deteriorating the patient’s condition. 相似文献
6.
Ishitani Ken Isoai Ayako Ito Tetsuya Sugiyama Hiroshi Arakawa Atsushi Yamada Yosuke Onodera Hirokazu Kobayashi Ryosuke Torii Naoko Soneda Noriko Matsuno Yoshihiro Utsugisawa Taiju Kato Michio Hanafusa Norio 《International journal of clinical oncology / Japan Society of Clinical Oncology》2021,26(6):1130-1138
International Journal of Clinical Oncology - Cell-free and concentrated ascites reinfusion therapy (CART) has been suggested to be able to treat malignant ascites more safely and effectively with... 相似文献
7.
Hanako Nakajima Yoshitaka Hashimoto Ayumi Kaji Ryosuke Sakai Fuyuko Takahashi Yuta Yoshimura Ryo Bamba Takuro Okamura Noriyuki Kitagawa Saori Majima Takufumi Senmaru Hiroshi Okada Naoko Nakanishi Emi Ushigome Mai Asano Masahide Hamaguchi Masahiro Yamazaki Michiaki Fukui 《Journal of diabetes investigation.》2021,12(7):1202-1211
8.
Yukihito Kuroda Tatsuya Oda Osamu Shimomura Shinji Hashimoto Yoshimasa Akashi Yoshihiro Miyazaki Kinji Furuya Tomoaki Furuta Hiromitsu Nakahashi Pakavarin Louphrasitthiphol Bryan J Mathis Takahito Nakajima Hiroaki Tateno 《International journal of cancer. Journal international du cancer》2023,152(7):1425-1437
Pancreatic ductal adenocarcinoma (PDAC) is resistant to current treatments but lectin-based therapy targeting cell surface glycans could be a promising new horizon. Here, we report a novel lectin-based phototherapy (Lec-PT) that combines the PDAC targeting ability of rBC2LCN lectin to a photoabsorber, IRDye700DX (rBC2-IR700), resulting in a novel and highly specific near-infrared, light-activated, anti-PDAC therapy. Lec-PT cytotoxicity was first verified in vitro with a human PDAC cell line, Capan-1, indicating that rBC2-IR700 is only cytotoxic upon cellular binding and exposure to near-infrared light. The therapeutic efficacy of Lec-PT was subsequently verified in vivo using cell lines and patient-derived, subcutaneous xenografting into nude mice. Significant accumulation of rBC2-IR700 occurs as early as 2 hours postintravenous administration while cytotoxicity is only achieved upon exposure to near-infrared light. Repeated treatments further slowed tumor growth. Lec-PT was also assessed for off-target toxicity in the orthotopic xenograft model. Shielding of intraperitoneal organs from near-infrared light minimized off-target toxicity. Using readily available components, Lec-PT specifically targeted pancreatic cancer with high reproducibility and on-target, inducible toxicity. Rapid clinical development of this method is promising as a new modality for treatment of pancreatic cancer. 相似文献
9.
10.